The world's first approved multi-target anti-cancer drug
Sorafenib is an oral multi-target receptor tyrosine kinase inhibitor, which can block tumor cell proliferation, inhibit angiogenesis, and induce tumor cell apoptosis. It has good anti-tumor activity and is mainly used in the treatment of advanced renal cell carcinoma. At present, it is also the first molecular targeted drug with good efficacy in the treatment of liver cancer.
Indications:
Unresectable hepatocellular carcinoma.
Advanced renal cell carcinoma.
Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment.
STRENGTH:
200mg/tablet
Download instructions
Contact us